[Strategy for treatment of acute lymphoblastic leukemia].

The treatment outcomes of adult acute lymphoblastic leukemia (ALL) have improved. Furthermore, the introduction of pediatric specific therapies has enhanced ALL treatment results in adolescents and young adult (AYAs). Age-related molecular signatures have also been identified, such as Philadelphia chromosome (Ph)-like ALL and DUX4/ERG gene-associated ALL. The measurement of minimal residual disease (MRD) has enabled the early detection of patients susceptible to relapse, and they become candidates for hematopoietic stem cell transplantation (HSCT). However, new generation tyrosine kinase inhibitor (TKI) therapy has enabled the avoidance of HSCT in Ph-positive ALL cases. Novel agents targeting CD19 and CD22 molecules will be available in the near future that should improve treatment outcomes in patients newly diagnosed with ALL.